News Release

Yamanouchi Pharmaceutical Co., Ltd.


November 12, 2001

Tokyo, Japan -November 11, 2001-Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) has started a collaborative research project on Alzheimer's disease with Bradley T. Hyman, M.D., Ph.D., and G. William Rebeck, Ph.D., Department of Neurology, Harvard Medical School, Massachusetts General Hospital (Massachusetts, USA), and Dudley Strickland, Ph.D., Head of the Department of Vascular Biology, American Red Cross Biomedical Services, Holland Laboratory (Maryland, USA).

The collaborative research will focus on mechanisms for the production of amyloid b peptide and the metabolism of amyloid b precursor protein, which are believed to be closely related to the onset of Alzheimer's disease. Researchers will determine if these mechanisms can be the basis for the discovery of drugs for Alzheimer's disease and construct a screening system in order to develop drugs that prevent progression of the disease. The collaborative research program also includes the production of a new animal model for Alzheimer's disease and evaluation of the potential clinical usefulness of compounds using the newly produced model. Starting from basic research, the program ultimately aims at discovering candidate compounds for new Alzheimer's disease drugs within a short time frame.

The collaborative effort between Dr. Hyman's and Dr. Strickland's groups has led to significant advancements in the understanding of Alzheimer's disease. Their recent contributions have attracted keen attention from Alzheimer's disease researchers around the world. Yamanouchi highly appreciates their research, experience and research network and believes that collaboration with this group will result in significant achievements.

While expanding its own drug discovery research programs based on genomics and other advanced technology, Yamanouchi is actively carrying out joint research and development programs with other drug companies, universities and venture companies. It is collaborating with GlaxoSmithKline and the Hospital for Joint Diseases of the New York University Medical Center. It has also concluded a contract with Celera Genomics to use Celera's genomic database. Yamanouchi plans to continue to actively promote strategic alliances with universities and venture companies while expanding its own drug discovery system in order to fill its new drug pipeline.